There's life after Namenda

The fortunes of Neurobiological Technologies Inc. have long been tied to its Namenda memantine, which is marketed for Alzheimer's disease (AD) by Forest Laboratories Inc. NTII receives a 1% royalty on those sales, but suffered a blow last year when Namenda failed a Phase III trial in diabetic

Read the full 487 word article

How to gain access

Continue reading with a
two-week free trial.